What to stack with retatrutide is a question increasingly asked in weight management and research communities, yet it carries significant clinical and regulatory caveats. Retatrutide (LY3437943) is an investigational triple receptor agonist — targeting GLP-1, GIP, and glucagon receptors simultaneously — that has not received UK marketing authorisation from the MHRA or approval from the EMA. It remains restricted to regulated clinical trials. This article explores what is currently known about combining retatrutide with other substances, outlines the relevant safety considerations, and explains what UK clinical guidance says about combination approaches to weight management.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, with no current MHRA or EMA marketing authorisation; it is restricted to regulated clinical trials and is not NHS-endorsed.

Retatrutide (LY3437943) is an investigational triple receptor agonist currently undergoing Phase 3 clinical trials. It targets three key hormonal receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple-action mechanism distinguishes it from existing agents such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GLP-1/GIP receptor agonist), and may offer enhanced effects on weight reduction and metabolic regulation, though the full clinical profile is still being established.

By activating GLP-1 receptors, retatrutide promotes insulin secretion, suppresses glucagon release, and reduces appetite. The GIP component may further support metabolic function, though the precise contribution of GIP receptor agonism to weight loss and insulin sensitivity in humans remains an area of active research. Glucagon receptor activation may increase energy expenditure; however, it can also raise hepatic glucose output and heart rate, and the net clinical effects of this component in humans are still being characterised in ongoing trials.

It is important to note that, at the time of publication, retatrutide has not received a UK marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA). Supply is generally restricted to regulated clinical trial settings. Products offered online or through unverified suppliers are likely to be unauthorised or counterfeit, and their use carries serious health risks. This is not endorsed by the NHS or NICE. Patients are strongly advised not to source retatrutide outside of a regulated clinical trial, in line with MHRA guidance on purchasing medicines online.

Common Supplements and Medications Used Alongside Retatrutide

No supplement or medication combination is clinically validated or UK-endorsed for use with retatrutide; any concurrent use of protein supplements, creatine, vitamins, metformin, or other agents requires individual clinical assessment.

Given that retatrutide has no UK marketing authorisation, the concept of 'stacking' it with other agents is not supported by any current clinical protocol in the UK. However, within research and online communities, individuals sometimes enquire about combining it with other substances. The following information is provided for educational and safety purposes only, and does not constitute a recommendation.

Some individuals using investigational or licensed GLP-1-based therapies have been known to use the following alongside them — though none of these combinations have been formally validated for retatrutide:

• Protein supplements: High-protein dietary intake is sometimes used to help preserve lean muscle mass during significant caloric restriction associated with weight-loss therapies. A target of approximately 1.2–1.6 g of protein per kg of body weight per day is commonly referenced in weight management literature, though this should be individualised and reviewed by a dietitian. People with chronic kidney disease (CKD) should not increase protein intake without specialist advice, as higher intakes may be contraindicated.

• Creatine monohydrate: Occasionally used to support muscle retention and exercise performance during caloric restriction. As with higher protein intakes, creatine is not appropriate for everyone, particularly those with impaired kidney function, and should only be used following a clinical assessment.

• Vitamin and mineral supplements: Targeted supplementation may be appropriate where deficiencies are confirmed by blood testing — for example, vitamin D or iron deficiency. Vitamin B12 deficiency is more commonly associated with long-term metformin use or restrictive dietary patterns than with GLP-1-based therapy itself, and supplementation should be guided by assessment rather than assumed. Routine supplementation without confirmed deficiency is not recommended.

• Metformin: In clinical trials for obesity and type 2 diabetes, metformin is sometimes used alongside GLP-1-based agents under medical direction. This combination should only be initiated and monitored by a clinician, in line with BNF and NICE guidance.

• Statins or antihypertensives: Individuals with cardiometabolic conditions may already be prescribed these medications, and their continuation alongside weight-loss therapies is typically managed by a clinician.

No supplement or medication should be assumed safe to combine with retatrutide without a thorough clinical assessment. No pharmacological 'stack' is recommended or UK-endorsed for retatrutide outside of regulated clinical trials.

Potential Interactions and Safety Considerations

Retatrutide's multi-receptor activity creates clinically significant interaction risks, including hypoglycaemia with insulin or sulphonylureas, worsened gastrointestinal effects, pancreatitis, gallbladder disease, and dehydration-related acute kidney injury.

Because retatrutide acts on multiple hormonal pathways, the potential for interactions with other substances — both prescribed and over-the-counter — is a genuine clinical concern. Evidence from approved GLP-1 receptor agonists provides relevant context, though it is important to note that some interactions are agent-specific rather than class-wide effects.

Hypoglycaemia risk is a key concern when GLP-1-based agents are combined with insulin or insulin secretagogues such as sulphonylureas. Retatrutide's insulin-stimulating properties could amplify this risk. Patients on such medications require careful blood glucose monitoring and possible dose adjustments, in line with BNF guidance. People with diabetes who drive should follow current DVLA guidance on hypoglycaemia and fitness to drive.

Gastrointestinal effects — including nausea, vomiting, diarrhoea, and delayed gastric emptying — are common with GLP-1-based therapies. Combining retatrutide with other agents that affect gut motility, such as opioids or anticholinergic drugs, could worsen these effects or alter the absorption of orally administered medications. Regarding oral contraceptives specifically, a clinically relevant interaction with delayed gastric emptying has been documented for tirzepatide in its UK Summary of Product Characteristics (SmPC), which advises the use of a non-oral or additional contraceptive method during initiation and dose escalation. Whether this applies to retatrutide is not yet established; patients should discuss contraceptive choices with their clinician. Similarly, any potential effect on thyroid hormone absorption should be assessed on an individual basis rather than assumed as a class effect.

Pancreatitis and gallbladder disease are recognised safety signals associated with the GLP-1 receptor agonist class. Patients should be advised to seek urgent medical attention if they develop severe abdominal pain, particularly pain radiating to the back, accompanied by nausea or vomiting, or right upper quadrant pain with jaundice or fever. These symptoms may indicate pancreatitis or gallbladder disease and require prompt evaluation.

Dehydration and acute kidney injury (AKI): Persistent vomiting or diarrhoea associated with GLP-1-based therapy can lead to dehydration. Patients should maintain adequate fluid intake and seek medical advice if they experience persistent vomiting with reduced urine output, particularly if they are also taking medicines that affect kidney function (such as NSAIDs, diuretics, or ACE inhibitors).

Herbal supplements and unregulated products present additional risks. Substances such as berberine, which has glucose-lowering properties, or stimulant-based fat burners, could interact unpredictably with retatrutide's metabolic effects. There is no evidence base for these combinations alongside an investigational agent.

Patients should also be aware that muscle loss during rapid weight reduction is a documented concern with potent weight-loss agents. Combining retatrutide with anabolic substances or performance-enhancing drugs — as sometimes discussed in online forums — is not clinically sanctioned and may carry serious cardiovascular and endocrine risks.

What UK Clinical Guidance Says About Combination Approaches

NICE does not address retatrutide as it holds no UK marketing authorisation; combination pharmacotherapy for obesity is not recommended outside clinical trials, and the MHRA warns against purchasing unlicensed weight-loss medicines online.

Current NICE guidance on the management of obesity does not address retatrutide, as it has no UK marketing authorisation. For context, NICE has issued technology appraisals for semaglutide (Wegovy) for weight management and for tirzepatide (Mounjaro) for weight management, each with specific eligibility criteria based on BMI and the presence of weight-related comorbidities. These appraisals set out the structured clinical framework within which approved anti-obesity pharmacotherapy may be offered in the UK. Combination pharmacotherapy for obesity is not currently recommended outside of clinical trials.

NICE-recommended approaches to obesity management emphasise a multidisciplinary framework that includes dietary intervention, physical activity, behavioural support, and — where appropriate — pharmacotherapy or bariatric surgery. Access to anti-obesity medicines through NHS services is generally subject to BMI thresholds (typically BMI ≥35 kg/m², or ≥30 kg/m² with relevant comorbidities, though criteria vary by appraisal) and is delivered within a structured care pathway.

The NHS Long Term Plan and NHS England's specialised weight management services outline a tiered approach to obesity treatment. Tier 3 and Tier 4 services involve specialist input before any pharmacological or surgical intervention is considered. This structured pathway is designed to ensure patient safety and clinical appropriateness — a principle that applies equally to any investigational agent such as retatrutide.

The MHRA has issued repeated warnings about the risks of purchasing unlicensed weight-loss medicines online, including counterfeit or substandard products. Combining such products with other substances — whether prescribed, over-the-counter, or supplementary — without medical oversight significantly increases the risk of adverse events.

If you suspect you have experienced a side effect from any medicine, including an unlicensed product, you can report it directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. Healthcare professionals are also encouraged to report adverse events associated with unlicensed medicines via this route.

Lifestyle Factors That May Support Retatrutide Treatment

Evidence-based lifestyle measures — including a nutrient-dense diet, resistance and aerobic exercise meeting UK CMO guidelines, improved sleep, stress management, and alcohol reduction — are appropriate complements to weight-loss pharmacotherapy.

Whilst pharmacological combinations remain clinically unsupported for retatrutide at this stage, there is robust evidence that certain lifestyle interventions can meaningfully complement weight-loss pharmacotherapy. These are consistent with NICE guidance and NHS recommendations, and are likely to remain relevant if retatrutide is eventually approved.

Dietary quality plays a central role. A balanced, nutrient-dense diet — rich in vegetables, lean protein, wholegrains, and healthy fats — supports the metabolic improvements associated with GLP-1-based therapies. Adequate protein intake is particularly important to help preserve muscle mass during weight loss. Commonly referenced targets in weight management literature are approximately 1.2–1.6 g per kg of body weight per day, though this should be individualised with input from a registered dietitian. People with CKD or other conditions affecting protein metabolism should seek specialist dietary advice before increasing protein intake.

Resistance and aerobic exercise are both beneficial. Resistance training helps maintain skeletal muscle during caloric restriction, whilst aerobic activity supports cardiovascular health and insulin sensitivity. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity activity per week for adults, alongside muscle-strengthening activities on two or more days.

Sleep and stress management are often overlooked but clinically significant. Poor sleep quality and chronic psychological stress are associated with dysregulation of appetite hormones, including ghrelin and leptin, which could undermine the benefits of weight-loss treatment. Cognitive behavioural approaches and mindfulness-based interventions have evidence supporting their role in weight management programmes, in line with NICE behavioural support recommendations.

Alcohol reduction is advisable. Alcohol contributes excess calories and may worsen gastrointestinal side effects associated with GLP-1-based agents. General NHS guidance recommends keeping alcohol intake to no more than 14 units per week, spread across several days, with alcohol-free days.

Speaking to a Healthcare Professional Before Combining Treatments

Consulting a GP, pharmacist, or specialist before combining retatrutide with any other substance is a patient safety imperative, covering medication interactions, nutritional assessment, contraception, and monitoring for serious adverse effects.

If you are considering using retatrutide — whether within a clinical trial or otherwise — it is essential to speak with a qualified healthcare professional before combining it with any other substance, including supplements, over-the-counter products, or prescribed medications. This is not merely a precautionary recommendation; it is a patient safety imperative.

A GP, pharmacist, or specialist clinician can:

• Review your current medication list for potential interactions, particularly with diabetes medications, anticoagulants, thyroid treatments, and hormonal contraceptives

• Assess your nutritional status and advise on appropriate supplementation only where deficiencies are confirmed

• Monitor for adverse effects such as hypoglycaemia, gastrointestinal disturbance, or unexpected changes in blood pressure or heart rate

• Refer you to appropriate NHS services, including Tier 3 weight management programmes, if you are seeking structured support for obesity

• Discuss contraception and family planning, as retatrutide should not be used during pregnancy or breastfeeding; reliable contraception should be in place, and any plans to conceive should be discussed with a clinician before starting or stopping treatment

If you experience any of the following whilst using retatrutide or any weight-loss agent, seek prompt medical attention:

• Severe or persistent nausea, vomiting, or abdominal pain — particularly pain radiating to the back, which may indicate pancreatitis

• Right upper quadrant pain, jaundice, or fever, which may suggest gallbladder disease

• Persistent vomiting with reduced urine output or signs of dehydration

• Signs of low blood sugar (shakiness, sweating, confusion, dizziness)

• Rapid or irregular heartbeat

• Unexplained muscle weakness or pain

• Rash, swelling of the face or throat, or difficulty breathing, which may indicate a serious allergic reaction

Retatrutide has no UK marketing authorisation; supply is generally restricted to regulated clinical trials. Products offered online or through unverified channels are likely to be unauthorised or counterfeit, and their use is unsafe. The MHRA advises strongly against sourcing any unlicensed medicine through unverified online suppliers.

If you believe you have experienced a side effect from any medicine or unlicensed product, please report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. Engaging with your healthcare team ensures that any weight management strategy you pursue is both safe and appropriately monitored, in line with the best available evidence and UK regulatory standards.

Frequently Asked Questions